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Abstract
Screening for novel producer strains and enhanced therapeutic production at 
reduced cost has been the focus of most of the biopharmaceutical industries. The 
obligation to carry out prolonged intensive pilot scale experiments gave birth to  
micro-scale bioreactor systems. Screening large number of microorganisms 
using shake flasks and benchtop bioreactors is tedious and consumes resources. 
Microbioreactors that mimic benchtop bioreactors are capable not only of high 
throughput screening of producer strains, but also aid in optimizing the growth kinet-
ics and expression of proteins. Modern technology has enabled the collection of precise 
online data for variables such as optical density (OD), pH, temperature, dissolved 
oxygen (DO), and adjusting in mixing inside microreactors. Microbioreactors have 
become an irreplaceable tool for biochemical engineers and biotechnologists to per-
form a large number of experiments simultaneously. Another aspect that is vital to any 
industry is the product yield and subsequent downstream processing. Perfusion biore-
actors are one of the upcoming advances in bioreactor systems that have the potential 
to revolutionize biologics production. This chapter intends to take a review of different 
aspects of microbioreactors and perfusion bioreactors including their potential in high 
throughput pilot studies and microbial and mammalian cell cultivation technologies.
Keywords: microbioreactors, biopharmaceuticals, bioprocess, perfusion 
microbioreactors, microorganisms
1. Introduction
1.1 Need for microbioreactors in bioprocess development
Microbioreactor systems are an integral part of bioprocess engineering. In the past 
few years, microbioreactors have extensively been used for high throughput screening 
[1]. In addition to this, extensive bioprocess experiments were monitored and con-
trolled. Industries involved in bulk production of pharmaceuticals, chemicals, enzymes 
for feed and food from microbial cell factories are in need of microbioreactors [2–4]. 
Advanced shaker microliter cultivation devices or down-scaled stirred tank reactors 
are two basic microbioreactors. Primary and secondary screening experiments based 
on microbial library are conducted in shake flasks and micro liter plates. This screen-




Comparison of workflow for traditional bioreactors and microbioreactors.
selected microbial candidates are subjected to lab-scale experimental conditions for 
better bioprocess control. Bioprocess method developed by microbioreactors is followed 
by successful lab-scale testing, and it is transferred to pilot scale. Pilot scale experiments 
are essential to understand the bioreactor inhomogeneities which can ultimately be 
addressed using simulators that can scale down the process of bioreactors [5, 6].
Traditional microbiorector experiments start from primary screening; followed 
by secondary screening using shake flasks; then, process development; and, finally, 
optimization leading to process validation and pilot scale. It is worth mentioning 
that microbioreactors reduce the number of steps involved in traditional bioreactors. 
Microbioreactors start with primary screening, followed by accelerated bioprocess 
development for secondary screening, resulting in process validation and pilot scale 
at a faster rate. Introduction of bioreactors has reduced the number of steps involved 
in traditional bioreactors to scale up the bioprocesses. Hence, microbioreactors have 
proved to me more economical as they reduce the usage of secondary screening by 
shake flasks, thus making the process development and optimization more efficient. 
Ecology and environmental concerns arising during traditional bioprocess develop-
ment have also been addressed by microbioreactors. Therefore, the focus of this 
chapter is on new developments in microbioreactors and their impact on bioprocesses.
1.2 Advantages and expected outcome of microbioreactors
Microbioreactors have numerous advantages over traditional bioreactors dur-
ing bioprocess development. Microbioreactors are necessary for high throughput 
quantitative microbial phenotyping under controlled experimental conditions. 
Microbioreactors reduce the time involved in the traditional bioprocess develop-
ment by replacing the shake flasks and large lab-scale bioreactors (Figure 1). 
Microbioreactors are more than necessary with specifications for efficient and 
economical bioprocess development. Expected outcomes of microbioreactors 
are as follows: (a) reduction in volume for each cultivation experiment; (b) time 
conservation during experiments; (c) simple, friendly, and operational without 
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fail; (d) automated operation with minimal or no supervision; (e) examination of 
bioprocess variables with high resolution; (f) temperature, pH, and feeding profiles 
for controlled cultivation process; (h) culture accessibility for sampling and dosing; 
(i) cultivation by fed-batch, batch, and continuous modes; (j) robotic systems with 
advanced hardware and software; and (k) scalability is compared to laboratory 
bioreactors [7].
For realizing all the above-mentioned desired properties of microbioreactors, 
researchers are emphasizing on applied and basic research. Extensive research has 
resulted in various microbioreactors with different technologies and applications.
2. Types of microbioreactors
Commercially available microbioreactors are based on their applications, 
specifications, and capabilities. Different types of microbioreactors are born out of 
extensive basic and applied research.
Biolector (m2p-labs.com), a commercial microbioreactor manufacturer, had 
developed microbioreactors for organism phenotyping, screening the strains, 
toxicity screening, and optimization of feed and growth parameters. These bioreac-
tors support single-use 48-well plates that can hold culture volume of 0.8–2.4 ml. 
Biomass formation can be monitored via fluorescence and by optodes pH and dis-
solved oxygen (DO). This system is integrated with liquid handlers for pH adjust-
ment; feeding; sampling; and control over temperature, gas, and humidity [8].
Microbioreactors (32 plate and 48 plate) [9] from Biolector were used for opti-
mization of feeding rate, media screening, and fermentation parameters for anaero-
bic and microaerophyllic organisms. Few other applications that are possible with 
biolector microbioreactors are growth characterization, high throughput protein 
characterization, enzyme and cell activity tests, functional genomics and proteomic 
studies, inhibition and toxicity studies, and quality control.
RoboLector [10] is another microbioreactor where microbioreactor system from 
biolector is interfaced with liquid handling robot. These microbioreactors with the aid 
of 48 or 96 parallel cultivations through microplates provide fermentation data repeat-
edly for every 5–15 minutes. In addition to this, a robotic system also controls nutrient 
feeding, adjusts pH by adding acid or base, and does sampling based on user definition.
Another commercial manufacturer Micro-24 (pall.com) [11] developed a 
microbioreactor for screening strains and cell lines besides optimization of growth 
and feed parameters. These microbioreactors support single-use cassettes with 24 
columns with culture volume ranging from 3 to 7 ml and regulate pH using ammo-
nia, carbon dioxide, and control over temperature.
Microbioreactors to study biotransformation, phenotyping, strain and toxicity 
screening were developed by commercial manufacturer Bioscreen C (bioscreen.
fi). These microbioreactors consist of two parallel 100-well plates with a capacity 
to hold culture volume of 0.4 ml. Optical density was used for quasi-continuous 
monitoring of biomass.
Growth profiler (enzyscreen.com), Applikon (applikonbio.com), SensorDish 
Reader (presens.de), ambr 15 (tapbiosystems.com), bioReactor (emag.de), and 
Sartorius (Sartorius.com) are other manufacturers of microbioreactors for various 
applications as per the requirements of clients.
2.1 Microbioreactors for fed-batch cultivation of Escherichia coli
During recombinant protein expression, E. coli synthesizes proteins at a faster 
rate with low multiplication rate. In traditional microbioreactors, fed-batch 
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cultivations of E. coli were performed by stirred tank reactors [1]. Carbon source, 
magnesium, and ammonium were used as feeding solutions to match the nutri-
tional requirements. It is worth mentioning that two fed-batch cultivations can be 
performed simultaneously with different nutrient compositions in the RoboLector 
systems. For example, feeding solution of one set of reaction is constituted with 
1 M sodium hydroxide, 400 g/l glycerol, 100 g/l ammonium phosphate, and 1 g/l 
of magnesium sulfate 7H2O whereas that of another set is composed of 200 g/l 
glycerol, 100 g/l ammonium phosphate, 2 g/l of magnesium sulfate 7H2O, and 
1 M NaOH. Cultivations were performed at a shaking frequency of 1100 rpm with 
diameter 3 mm and temperature was set at 30°. Modified medium with 10 g/l 
glycerol and 100 mM MOPS with minimum salt was used. Online-monitored DO 
measurements were used to control the repeated additions of feeding solutions and 
both the feeding methods resulted in high cell densities of approximately 80 OD 
besides pH stabilization in between 6.5 and 7 for favorable growth of E. coli. Both 
the cultivations, one with high volume of glycerol and another with low volume of 
the same, exhibit high biomass concentration. Traditional bioreactors need huge 
amounts of energy for mixing, heating, and cooling during scale-up process but 
RoboLector microbioreactors are efficient and precise to hasten the development of 
bioprocesses using microbial cells [1].
2.2 Cultivation of Pichia pastoris using microbioreactors
Secreted proteins during bioprocesses undergo proteolysis and fragmentation; 
therefore, samples are generally removed from fermentation broth to obtain a 
kinetic growth curve. The purpose is to identify the optimum cultivation setup 
to reach maximum activity for the recombinant enzyme. RoboLectors are used to 
understand the kinetics of Pichia pastoris fed-batch cultivation [1]. Kinetics was 
monitored online by drawing 20 μl automatically and the concentrations of secreted 
enzymes were plotted against time to identify the space-time yield. During the 
automatic pipetting process, robotic tips immersed in the solution without any 
shaking, thus preventing artifacts of sedimentation.
To increase the productivity, softwares are programmed to provide outline of the 
experiments as per the input parameters. Dosing volume and variations in the concen-
trations of glycerol, ammonium hydroxide, and methanol can be given in the inputs. 
In 48 parallel fed-batch cultivations, a factorial design play gives a value, 24 + 3 = 19; 
these different possibilities can be performed in one single analysis. Once the experi-
ment is completed, the system automatically generates a contour plot and summarizes 
the activity profile of the recombinant enzymes with respect to the dosing volume and 
feeding solutions. For a particular recombinant product from Pichia pastoris, following 
factors were summarized at the completion of the experiment: 35% v/v methanol, 
25% w/w ammonium hydroxide, and 150 g/l as feed composition for a dosing volume 
of 5 μl. The above-mentioned experiment is repeated for a particular design to identify 
and confirm the variable factors and increase the productivity [1].
2.3 Microbioreactors to produce monoclonal antibodies
Monoclonal antibodies are one of the major products among biotherapeutics. 
Organisms such as Chinese hamster ovary (CHO) and human embryonic kidney 
(HEK) cells are utilized to produce monoclonal antibodies, and several biopro-
cess parameters need to be optimized [12, 13] for their production. Composition 
of culture media, cell growth rate, and antibody growth rate need favorable 
physicochemical parameters such as pH, temperature, and dissolved oxygen. 
Physicochemical parameters are controlled to initiate and sustain recombinant 
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expression in the CHO cell culture and to provide nutrients and relevant growth 
factors to bioreactors. During the production of monoclonal antibodies, pos-
sibilities of forming various variants of immunoglobulin (IgG) molecule and 
glycosylated IgG forms can be seen. Similar to monoclonal antibodies, other protein 
therapeutics also pass through issues such as oxygenation, amination, and degraded 
product molecules. Each of these above-mentioned processes is lengthy and con-
sumes enormous time during research and development (R&D).
Microbioreactors, due to their miniature size and parallel testing, are needed 
to accelerate research and development (R&D) at a faster pace. Microbioreactors 
encompassed with sensors [14] that can hold volume in the range of 1–20 μl are 
ideal to monitor the bioprocess parameters. Microbioreactors need to be designed 
as per the needs of users. For example, for users to develop bioprocess procedures 
for mammalian cell cultures, the list of biological functions of mammalian cells and 
technical functions of bioreactors becomes essential.
Biological functions and requirements include: (a) nature of the cells (CHO or 
HEK cells) with concentration ranging from 10,000 to 10,000,000, (b) expression of 
proteins such as IgGs, (c) serum-free medium, and (d) culture time of 7–14 days [15].
Technical information parameters must include: (a) shaking for better mixing, 
(b) oxygen transfer value >100 h−1 to aerate the culture so that it can be extended to 
a large-scale process, (c) oxygen permeability <1%, (d) surface hydrophobicity (10°) 
along with a confocal microscope installed in situ without disturbing the reaction, 
(e) cell culture volume, (f) transportation of culture media to contained culture, and 
(g) measurement of chemical and physical conditions of culture and media [15].
Information function, namely online or offline information, is also essential: (a) 
online information about sensors to control and detect pH, temperature, and pO2 is 
significant and (b) offline information such as monomers in culture media, forms 
of IgGs, excreted metabolites, products formed, and residual nutrients is needed for 
analysis of analytes. It is important that microbioreactors should be designed as per 
the specifications based upon the above requirements.
These specifications also cater to the requirements of microbioreactors in 
laboratories with 2–5-liter capacity. Therefore, such processes could be scaled up to 
laboratory level with effortless ease at reduced cost. CHO cell culture microbioreac-
tors used to optimize the production of monoclonal antibodies are schematically 
shown in Figure 2. This is a part of Hubka-Eder map [16] focused on biological and 
technical functions. Hubka-Eder map shows the importance of integration among 
the subsystems, that is, the expression systems, cell line, medium with various 
technical and information functions for the design of the microbioreactors for the 
maximum production of monoclonal antibodies [15].
2.4 Microbioreactors in drug discovery
Organ-on-a-chip [17] is an ongoing research to hasten the process of drug discov-
ery and development. In vitro drug screening and safety testing [18–20] are essential 
to minimize extensive studies on laboratory animals. Microbioreactors designed as 
per the need of the study will be highly beneficial to understand the potency and 
toxicity of the developed drug molecules. Drug molecules upon absorption get dis-
tributed to various organs such as lung, liver, gut, intestine, etc. These organs majorly 
consist of enzymes that can metabolize the drug molecules to metabolites [21] which 
can either be potent or toxic. After metabolism, the drug and its metabolites need 
to reach the target site for a particular time and get eliminated from the circulating 
system [22]. Kidneys play an important role in excreting drugs and its metabolites. 
Hence, developing various organs on a chip, programmed through a microbio-
reactor will be very helpful to understand the safety of drugs and metabolites. 
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Heart-on-a-chip is one such device which is developed to understand the efficacy of 
drug molecules with cardiac cells. Studies have proved that these devices have the 
capability to lend a helping hand in drug discovery and development process.
3. Perfusion Bioreactors
3.1 Perfusion technology for biopharmaceutical production
The leading focus of R&D of any biopharma-based industry is to develop 
production process at reduced cost of production or rather work toward a minimal 
Cost of Goods (CoG) for cell culture-based products. Fed-batch mode of produc-
tion has been the most tried and tested one, documented and dominantly followed 
methodology for production of biologics or biopharmaceuticals from mammalian 
cell culture. Due to the presence of expertise on this process within the industry, it 
has been proved to be the efficient process with judicious use of media coupled with 
a hassle-free downstream process. However, fed-batch mode has a severe limitation 
of inhibition of product formation and cell growth due to accumulation of inhibi-
tory products during culture, especially ammonium ions, lactates, and proteases 
[23]. This leads to loss of key nutrients and incurs massive financial and resource 
loss to the production setup. This is especially significant if the product is a sensitive 
one. An alternative to this technology that came up in the early 1990s is perfusion 
technology. It involves addition of media or key media constituents at regular 
intervals along with retention of cells in the reactor and harvesting of formed 
products. However, in the initial phase, due to less advancement in media formula-
tion and process development as well as dearth of efficient expression systems, not 
much advantage was offered by perfusion-based systems as compared to the well-
established fed-batch systems and, hence, perfusion technology faced many failures 
and could not progress significantly. Many companies involved in manufacturing 
of perfusion-based systems especially for hybridoma-based monoclonal antibodies, 
Figure 2. 
Bioprocess optimization of a CHO cell culture to produce monoclonal antibodies.
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like Endotronics, Cellex, and Biosyn, also folded up due to low market for perfusion 
bioreactors [24]. However, the pharma sector was on a constant lookout for newer 
or more effective production processes and hence advancements were continuously 
being made in perfusion technology. Now, with major advancements in media 
formulation, multiple technological options are available for cell retention and a ris-
ing trend has been witnessed in pharmaceutical industry for investment in adoption 
of new technologies and the cost effectiveness of perfusion-based processes, and 
their product yield increased significantly in comparison to conventional fed-batch 
processes [25]. Hence, this technology is on a comeback for the last few years and 
numerous life science companies are advocating the use of perfusion for biologicals 
production.
Factor VIII (ReFacto®) and IgG (Remicade® by Jansen Biotech and Simulect® 
by Novartis) are two of the leading products being produced commercially using 
perfusion technology [26, 27]. Apart from these, other products include interferon 
β-1a (Rebif from merck Sereno) and Ab Golimulab (Simponi® by Jansen Biotech), 
Factor VIII (Kogenate from Bayer Schering); anti-platelet MAb (ReoPro) and tumor 
necrosis factor MAb (Remicade from Centocor/J&J); CD52 a MAb (Campath from 
Genzyme/Sanofi); and a modified Factor VIII (Xyntha/ReFacto from Wyeth/
Pfizer) among others. This substantiates the wide application of perfusion-based 
technologies for a variety of biologicals. The growing need of the pharma sector for 
reduced cost and enhanced productivity led to the resurgence of perfusion-based 
production technologies which have the key to revolutionize biopharmaceutical 
production process from mammalian cells.
3.2 Why perfusion technology?
Perfusion-based bioreactors are one of the upcoming reactor technologies based 
on continuous bioprocessing that offers the ease of continuous culturing of cells 
without nuisance of filter clogging or low throughput. In addition, there are less 
possibilities of waste accumulation and, hence, minimized chances of any product 
inhibition, especially while dealing with proteins prone to instability. Since nutri-
ents are continuously exchanged and product harvest is maintained throughout 
along with cell retention, the availability of key media constituents is maintained 
consistently by providing host cells a stable environment leading to a high cell 
density and higher productivity with respect to desired compound. Typically, 
3–10 × 107 cells/ml is the titer achieved using perfusion as compared to 5–25 × 106 
in fed-batch cultures. Besides that, cost of goods in the 10,000–20,000-l fed-batch 
reactor is equivalent to that achieved using 1000 -l perfusion bioreactor [28]. Since 
the cells are subjected to a more stable and consistent environment, the recombi-
nant proteins and other molecules produced are more like native compounds with 
similar glycosylation pattern and biological activity. This further increases the 
stability of the product and gives a high product yield. In a recent economical com-
parison between fed-batch and perfusion mode for the production of a glycosylated 
protein, CoG was analyzed and compared for both the processes based on BioSolve 
software. Continuous perfusion was calculated and found to be the most productive 
technology giving product at the rate of 265 kg/year as compared to 130 kg/year in 
fed-batch mode. Perfusion was also found to be the most cost-effective mode with 
the lowest overall CoG of $87/g as compared to $118/g for the continuous fed-batch 
process [29]. Also, there are less possibilities of failure and economic loss. Even if a 
problem is encountered, only the part being processed would need to be discarded, 
saving the rest for further processing. In a comparative study on production by both 
perfusion and fed-batch modes, CMC Biologics reported yield of 425 mg/l/day from 
perfusion bioreactor as compared to a yield of only 55 mg/l/day from fed-batch 
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system for the same period of time [30]. Since most of the pharma companies thrive 
on economic profits, perfusion technology offers a lucrative mode of production 
especially as it beats the conventional fed-batch system in terms of productivity, 
efficiency, and capital investments.
3.3 Cell retention in perfusion
The prominent aspect which makes perfusion systems different and more 
valuable than fed-batch systems is the ability to yield a high cell mass due to the 
presence of cell retention devices. There are various ways through which cell reten-
tion is achieved [31]. Cells can be retained by making them grow inside bioreactor 
on hollow capillary fibers, flat plates, sponge-like materials, microcarrier particles, 
or other membranes. It can also be done by use of various cell separation devices 
like gravity-based cell settlers, spin filters, centrifuges, cross-flow filters, alternat-
ing tangential-flow filters, vortex-flow filters, acoustic settlers (sonoperfusion), 
and hydrocyclones [32]. Spin filter was one of the earliest available devices for 
cell retention which used a two-dimensional screen to retain the cells. However, 
it had limited scale-up potential especially in the scenario where rapid feed rate 
is needed. Gravity-based cell settlers are cost-effective but are marked by inef-
ficient cell separation and significant cell loss, which lowers output and increases 
cost. Centrifuges have been known to give good performance but increase the 
production cost. Alternating tangential-flow filters (TFFs) have emerged as the 
most effective and practical means of high-density cell retention in a perfusion 
bioreactor [33]. The alternating tangential-flow action in these filters and location 
of diaphragm in the system prevent clogging as well as ensure a faster return of 
cells back to the reactor, bringing complete clarification. However, what need to be 
worked upon are other reactor specifications for handling large cell load at reduced 
volume and culture time. Also, scalability complications are a deterrent for many 
manufacturers. Many companies are targeting advancements in ATF system to 
handle increased cell load at smaller reactor volume. In a recent report on biologics 
development and manufacturing, the advancement in perfusion and its leading 
incorporation in manufacturing processes by leading biologics-based companies 
was attributed mostly to the advancements made in ATF systems which enhance 
the cell titers by multiple folds over extended periods of time, leading to higher 
volumetric productivity [34]. Acoustic wave separation (AWS) is another technol-
ogy used by many companies for cell separation. Applikon Biotechnology and Pall 
Life Sciences are two such manufacturers advocating the use of acoustic waves to 
clump and settle down cells leading to their eventual separation. Sigma Aldrich Co. 
LLC (Merck & Co. Inc.), FiberCell Systems Inc., Zellwerk GmbH (Glen Mills in the 
United States), Cell Culture Company, ATMI Incorporated, PBS Biotech, Inc., GE 
Healthcare Life Sciences, Applikon Biotechnology, WAVE Life Sciences Biovest, 
AmProtein, Xcellerex, etc. are few of the leading manufacturers of perfusion 
bioreactors [35]. These reactors are revolutionizing the biopharmaceutical produc-
tion industry and have established their presence in this sector preferably to stay 
for many years to come.
3.4 Perfusion and microbioreactors
Integration of perfusion technology with microbioreactors enhances the 
advantages associated with microbioreactors effectively. It further minimizes the 
losses associated with batch failure due to contamination. Even if contamina-
tion occurs earlier in the process, lesser media and other consumables would 
be wasted. However, the compatibility of the setup is amenable to technology 
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development, scale-up, optimization, parameter sensitivity studies, and validation. 
Advancements in cell retention systems at microfluidic levels continue to be made. 
In a recent report, a novel microfluidic cell retention device based on inertial sort-
ing was tested positively for retention of IgG1-producing Chinese hamster ovary 
(CHO) cell line. Parameters tested were cell retention efficiency, biocompatibility, 
and scalability. This was a spiral membrane-less system accomplishing cell retention 
based on hydrodynamic forces. The device was fabricated with polydimethylsilox-
ane (PDMS) and connected to spinner vessel-containing cells. There was also the 
flexibility of configuring the device to separate different-sized cells with a specific 
input flow rate. This gave an added advantage of flushing out non-viable cells, 
thus creating a healthier environment for the productive cell batch, leading to an 
increased productivity and product specificity [36]. In a first-of-its-kind study 
on feasibility of growth of human embryonic stem cells (hESCs), in continuous-
flow microbioreactors, key cellular behavioral factors were assessed for robust 
cell growth under a range of flow rates. This would provide an assay platform for 
screening multiple cell lines for their capability to function in perfusion culture 
conditions as well as would aid in identifying optimum flow rates for their applica-
tion in other microfluidic cell culture systems. Such microfluidic reactor setups 
would help in better understanding of stem cells maintenance and differentiation 
under varying stimulation conditions [37]. Perfusion microfluidic systems can 
also be used for growth and expression of proteins from bacterial cells. Growth of 
suspended cultures of Pichia pastoris in microbioreactor, integrated with perfusion 
devices, established the feasibility of use of such integrated systems for suspended 
bacterial growth and expression. Expression of recombinant human growth 
hormone (rhGH) or recombinant interferon alfa-2b (rIFNα-2b) by Pichia pastoris 
was found to be maintained after 11 days of growth which is close to the duration 
of many industrial processes with duration lasting from 7 to 30 days. Success of this 
study establishes the feasibility of use of perfusion-capable bioreactors to study 
impact of perfusion culture on expression and process optimization of many other 
microbial systems [38] at microfluidic levels, thus saving the initial process devel-
opment costs [39].
3.5 Future of perfusion technology
Despite being in the sector for many years, perfusion technology did not gain 
much usage. However, with new methods for cell retention in the market and 
growing need for high throughput mammalian cell-based production systems, 
there is a renewed interest in the use of perfusion bioreactors. With a low capital 
and start-up cost, smaller setup, a smaller requirement for upstream and down-
stream processes, and reduced cost of failures, more and more compounds are 
being commercially produced using this technology. From leading biological 
manufacturers like Pfizer to upcoming ones like CMC Biologics, many companies 
are propagating the use of this technology with setup ranging from 250 to 2000 
liters. Current research, however, would focus on scalability of the technology, 
creating a robust cell retention system, high-yield cell lines used in single-use 
technologies, cutting down on the initial establishment cost and creating the avail-
ability of expertise in perfusion-based devices and also the ease of bioprocessing 
modeling during continuous mode of operation. Also of relevance and on the rise 
is the use of single-use perfusion-based reactors for production. There are many 
manufacturers dealing with development of single-use bioreactors, sensors, and 
other systems to simplify setup and operation of perfusion cell culture. These 
include among Pall Life Sciences, Applikon Biotechnology, Sartorius, AcuSyst, GE 
Healthcare, and many others.
Biotechnology and Bioengineering
10
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
4. Conclusion
Microbioreactors are essential for high throughput screening of various strains 
and optimize the bioprocess development in industries. Microbioreactors assist 
in identifying the appropriate experimental conditions to scale up the production 
process. Production of biopharmaceuticals, enzymes, proteins, and medicinally 
important chemical compounds from organisms was attempted successfully. 
Microbioreactors have been demonstrated as a suitable technology to cultivate 
Pichia pastoris, Escherichia coli, monoclonal antibodies, etc., at large scale that are 
important for biopharmaceutical industries. Incorporation of microbioreactors in 
drug discovery and development will reduce the cost and time for developing thera-
peutic molecules. The growing need for a high production process and efficient 
production strategy has also championed the cause of perfusion-based technology 
interfaced with microbioreactors. Perfusion microfluidic bioreactors have been 
extremely beneficial in maintaining stem cells, expression of proteins, growth of 
cells, and microbial cultures. Thus, microbioreactors aid in developing high-quality 
products at affordable cost with minimal resources.
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